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ABSTRACT 
 
Background: Hepatitis C virus (HCV) infection is a serious health problem 
worldwide. About 130 - 200 million people, and 1- 8% of all pregnant women 
were infected. It is a major contributor to end-stage liver disease. Women with 
viral hepatitis may be at an increased risk of pregnancy complications. Several 
obstetrics intervention act as risk factors which are specific to women pertaining 
the HCV infection; anti-D immunoglobulin (Ig) therapy may be one of them. The 
objectives of this sudy were to estimate the prevalence of HCV antibodies (anti-
HCV), RNA as well as HCV genotype among women with a history of anti-D Ig 
therapy. 
Subjects and Method: A cross sectional study was carried out involving 154 
Rhesus negative (Rh-ve) blood group pregnant women regardless of the anti-D Ig 
therapy.  Anti-HCV was tested using third generation enzyme immunoassay 
(EIA-3) and immunoblot assay (Lia Tek-111), subsequently. In addition, 89 serum 
samples were subjected to molecular analysis using RT-PCR and DNA enzyme 
immunoassay (DEIA) method for HCV-RNA and genotypes.  
Results: Anti-HCV and HCV-RNA seroprevalence were higher (17.1%, 35.5%) 
among recipients of anti-D Ig than their counter group (6.4%, 13.16%, 
respectively), and it was stastically significant (p= 0.038, p= 0.010, respectively). 
Significant direct positive dose response correlation (r= 0.78, p= 0.005) had been 
seen between number of anti-D Ig and anti-HCV seropositive rate. Anti-D Ig 
therapy act as a risk factor (OR= 3.01, 95% CI: 1.01 to 8.9) especially from the 
third dose onward. Women with anti-D Ig therapy were at higher risk (3.6 times 
more) of positive HCV-RNA (OR= 3.6, 95% CI= 1.19 to 10.837). HCV-1b showed 
higher prevalent (52.9%) among the recipients of anti-D Ig therapy while 
genotype HCV-3a (6.6%) was the lowest. 
Conclusion: This study showed that Anti-D immunoglobulin therapy acts as a 
risk factor for HCV infection. Screening for HCV is recommended for all 
recipients of anti-D Ig. Not only HCV antibodies but also HCV-RNA detection is 
recommended for the diagnosis of HCV infection. 
 
Keywords: maternal health, hepatitis C virus (HCV), anti-D immunoglobulin, 
HCV genotypes, risk factor  
 
Correspondence: Prof. Dr. Waqar Al-Kubais, Population Health and 
Preventive Medicine (PHPM). Faculty of Medicine, Universiti Teknologi MARA 
(UiTM), Sungai  Buloh Campus, Jalan Hospital, 47000, Sungai Buloh Selangor, 
Malaysia. Email: waqar_abd@yahoo.co.uk. Mobile: +60172731647. 
